Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Versant Capital Management Inc

Versant Capital Management Inc raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 51.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,058 shares of the biopharmaceutical company’s stock after buying an additional 361 shares during the period. Versant Capital Management Inc’s holdings in Gilead Sciences were worth $98,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. IMPACTfolio LLC acquired a new position in Gilead Sciences in the 4th quarter valued at about $220,000. Principal Financial Group Inc. grew its holdings in shares of Gilead Sciences by 4.3% in the third quarter. Principal Financial Group Inc. now owns 1,451,249 shares of the biopharmaceutical company’s stock valued at $121,673,000 after purchasing an additional 59,181 shares in the last quarter. Exome Asset Management LLC purchased a new stake in Gilead Sciences during the 3rd quarter worth approximately $4,192,000. Brass Tax Wealth Management Inc. acquired a new stake in Gilead Sciences during the 3rd quarter worth approximately $242,000. Finally, Garden State Investment Advisory Services LLC purchased a new position in Gilead Sciences in the 3rd quarter valued at approximately $221,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 8,500 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $91.96, for a total transaction of $781,660.00. Following the sale, the chief financial officer now owns 132,373 shares of the company’s stock, valued at approximately $12,173,021.08. The trade was a 6.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Merdad Parsey sold 164,211 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 453,734 shares of company stock valued at $41,902,086. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently weighed in on GILD. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Wolfe Research started coverage on Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective for the company. Piper Sandler upped their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Twelve analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $96.43.

Gilead Sciences Stock Down 0.5 %

Shares of Gilead Sciences stock opened at $91.41 on Friday. The company has a market cap of $113.92 billion, a P/E ratio of 1,015.67, a PEG ratio of 2.24 and a beta of 0.18. The firm has a fifty day moving average of $91.81 and a two-hundred day moving average of $82.40. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.29 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.37%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.